75 related articles for article (PubMed ID: 30113138)
1. Implementation of multiparametric magnetic resonance imaging technology for evaluation of patients with suspicion for prostate cancer in the clinical practice setting.
Shah PH; Patel VR; Moreira DM; George AK; Alom M; Kozel Z; Joshi V; Ben-Levi E; Villani R; Yaskiv O; Kavoussi LR; Vira M; Olsson CO; Rastinehad AR
BJU Int; 2019 Feb; 123(2):239-245. PubMed ID: 30113138
[TBL] [Abstract][Full Text] [Related]
2. Biomarker vs MRI-Enhanced Strategies for Prostate Cancer Screening: The STHLM3-MRI Randomized Clinical Trial.
Björnebo L; Discacciati A; Falagario U; Vigneswaran HT; Jäderling F; Grönberg H; Eklund M; Nordström T; Lantz A
JAMA Netw Open; 2024 Apr; 7(4):e247131. PubMed ID: 38648061
[TBL] [Abstract][Full Text] [Related]
3. Men's Acceptance of Screening for Prostate Cancer with Prostate-specific Antigen, Magnetic Resonance Imaging, and Prostate Biopsy.
Godtman RA; Pettersson C; Svensson L; Kohestani K; Stinesen Bratt K; Wallström J; Månsson M; Hellström M; Hugosson J
Eur Urol Oncol; 2024 Jun; 7(3):553-562. PubMed ID: 37993370
[TBL] [Abstract][Full Text] [Related]
4. Design of a magnetic resonance imaging-based screening program for early diagnosis of prostate cancer: preliminary results of a randomized controlled trial-Prostate Cancer Secondary Screening in Sapienza (PROSA).
Messina E; La Torre G; Pecoraro M; Pisciotti ML; Sciarra A; Poscia R; Catalano C; Panebianco V
Eur Radiol; 2024 Jan; 34(1):204-213. PubMed ID: 37561183
[TBL] [Abstract][Full Text] [Related]
5. Prospective Validation Study of a Novel Integrated Pathway Based on Clinical Features, Magnetic Resonance Imaging Biomarkers, and MicroRNAs for Early Detection of Prostate Cancer.
Pecoraro M; Catanzaro G; Conte F; Besharat ZM; Messina E; Laschena L; Trocchianesi S; Splendiani E; Sciarra A; Catalano C; Paci P; Ferretti E; Panebianco V
Eur Urol Oncol; 2024 Feb; 7(1):73-82. PubMed ID: 37270379
[TBL] [Abstract][Full Text] [Related]
6. [Prostate cancer screening-current overview].
De Vrieze M; Hübner A; Al-Monajjed R; Albers P; Radtke JP; Schimmöller L; Boschheidgen M
Radiologie (Heidelb); 2024 Jun; 64(6):479-487. PubMed ID: 38743100
[TBL] [Abstract][Full Text] [Related]
7. Prostate MRI Was Negative-What's Next?
Seibert TM
Cancer Epidemiol Biomarkers Prev; 2024 May; 33(5):641-642. PubMed ID: 38689575
[TBL] [Abstract][Full Text] [Related]
8. Multiparametric MRI in the PSA screening era.
George AK; Pinto PA; Rais-Bahrami S
Biomed Res Int; 2014; 2014():465816. PubMed ID: 25250323
[TBL] [Abstract][Full Text] [Related]
9. [Early detection of prostate cancer: Towards a new paradigm?].
Peyrottes A; Rouprêt M; Fiard G; Fromont G; Barret E; Brureau L; Créhange G; Gauthé M; Baboudjian M; Renard-Penna R; Roubaud G; Rozet F; Sargos P; Ruffion A; Mathieu R; Beauval JB; De La Taille A; Ploussard G; Dariane C
Prog Urol; 2023 Dec; 33(15-16):956-965. PubMed ID: 37805291
[TBL] [Abstract][Full Text] [Related]
10. Disparities in magnetic resonance imaging of the prostate for traditionally underserved patients with prostate cancer.
Quinn TP; Sanda MG; Howard DH; Patil D; Filson CP
Cancer; 2021 Aug; 127(16):2974-2979. PubMed ID: 34139027
[TBL] [Abstract][Full Text] [Related]
11. After PSA screening, MRI-targeted vs. systematic biopsy detected fewer clinically insignificant prostate cancers.
Hoffman RM
Ann Intern Med; 2023 Apr; 176(4):JC44. PubMed ID: 37011398
[TBL] [Abstract][Full Text] [Related]
12. Histomic and transcriptomic features of MRI-visible and invisible clinically significant prostate cancers are associated with prognosis.
Lehto TK; Pylväläinen J; Sandeman K; Kenttämies A; Nordling S; Mills IG; Tang J; Mirtti T; Rannikko A
Int J Cancer; 2024 Mar; 154(5):926-939. PubMed ID: 37767987
[TBL] [Abstract][Full Text] [Related]
13. Screening for Prostate Cancer.
Carlsson SV; Vickers AJ
Med Clin North Am; 2020 Nov; 104(6):1051-1062. PubMed ID: 33099450
[TBL] [Abstract][Full Text] [Related]
14. Normalised repeat serum prostate-specific antigen: associations with age and magnetic resonance imaging results.
Dang H; Huang V; Bratt O
Scand J Urol; 2024 Mar; 59():54-57. PubMed ID: 38446019
[TBL] [Abstract][Full Text] [Related]
15. How to read biparametric MRI in men with a clinical suspicious of prostate cancer: Pictorial review for beginners with public access to imaging, clinical and histopathological database.
Jambor I; Martini A; Falagario UG; Ettala O; Taimen P; Knaapila J; Syvänen KT; Steiner A; Verho J; Perez IM; Merisaari H; Vainio P; Lamminen T; Saunavaara J; Carrieri G; Boström PJ; Aronen HJ
Acta Radiol Open; 2021 Nov; 10(11):20584601211060707. PubMed ID: 34868663
[TBL] [Abstract][Full Text] [Related]
16. [Advances in the genetic diagnosis and treatment of prostate cancer].
Li J; Cao DH; Wei Q; Liu LR
Zhonghua Nan Ke Xue; 2022 Aug; 28(8):715-721. PubMed ID: 37838972
[TBL] [Abstract][Full Text] [Related]
17. Chronic Glucocorticoid Use and Risk for Advanced Prostate Cancer at Presentation: A SEER-Medicare Cohort Study.
Singh Z; Holt SK; Gore JL; Nyame YA; Wright JL; Schade GR
Clin Genitourin Cancer; 2024 Apr; 22(2):68-73.e2. PubMed ID: 37806926
[TBL] [Abstract][Full Text] [Related]
18. The role of PSA density in the MRI pathway for prostate cancer diagnostics.
Cash H; Schostak M
Prostate Cancer Prostatic Dis; 2023 Sep; 26(3):437-438. PubMed ID: 35882951
[No Abstract] [Full Text] [Related]
19. Clinically Translatable Hyperpolarized
Mu C; Liu X; Kim Y; Riselli A; Korenchan DE; Bok RA; Delos Santos R; Sriram R; Qin H; Nguyen H; Gordon JW; Slater J; Larson PEZ; Vigneron DB; Kurhanewicz J; Wilson DM; Flavell RR
ACS Sens; 2023 Nov; 8(11):4042-4054. PubMed ID: 37878761
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis of prostate cancer screening and MRI.
Takahashi T
World J Urol; 2024 Apr; 42(1):212. PubMed ID: 38578452
[No Abstract] [Full Text] [Related]
[Next] [New Search]
